Skip to content

Janux Therapeutics JANX Short-Term Investments

Short-Term Investments at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$363M+18.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.79B+10.1%
Vor Biopharma logo
Vor BiopharmaVOR
$321.65M+3,120%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$276.8M+21.8%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$419.03M+133%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$621M-22.9%

Other financials

Income statement

See full
Revenue$3.7M
Operating income-$34.2M+2.0%
Net income-$24.4M-3.6%
EPS (diluted)-$0.39-2.6%

Balance sheet

See full
Cash & equivalents$51.8M-29.7%
Total debt$21.6M-4.6%
Total equity$941.5M-7.0%
Total assets$1.0B-2.1%

Cash flow

See full
Operating cash flow-$12.3M+27.5%
CapEx$273.0K-26.4%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$892.81M-36.1%
Enterprise value$862.55M-35.9%
P/S65×-84.6×

Profitability

See full
Operating margin-1,143.1%-65.1pp
Net margin-833.6%+0.9pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-11.7%+4.1pp
Debt / equity0.0×
Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janux Therapeutics's short-term investments?
Janux Therapeutics (JANX) reported short-term investments of $904.56M in Q1 2026.
How has Janux Therapeutics's short-term investments changed year-over-year?
Janux Therapeutics's short-term investments decreased by 3.8% year-over-year, from $940.4M to $904.56M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.